Construction of IgG-Fab

Inteins Trans-Splicing Antibodies, Bispecific Protein Splicing Immunoglobulin G / genetics

Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
25 09 2023
Historique:
received: 12 07 2023
accepted: 20 09 2023
medline: 4 10 2023
pubmed: 26 9 2023
entrez: 25 9 2023
Statut: epublish

Résumé

A bispecific antibody (bsAb) is a class of engineered antibody molecules that simultaneously binds to two different antigens by having two kinds of antigen-binding domains. One of the major obstacles for the bsAb production is the incorrect chain-pairing problem, wherein each heavy and light chain should form pairings with the correct counterpart's chains, but the structural similarity of the incorrect partners also forms the incorrect pairings. This study aimed to demonstrate a bsAb construction method using intein-mediated protein trans-splicing to create IgG-Fab

Identifiants

DOI: 10.1038/s41598-023-43110-0 PMID: 37749185 PMC: PMC10520027
pubmed: 37749185
doi: 10.1038/s41598-023-43110-0
pii: 10.1038/s41598-023-43110-0
pmc: PMC10520027
doi:

Substances chimiques

Antibodies, Bispecific 0
Immunoglobulin G 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

15961

Informations de copyright

© 2023. Springer Nature Limited.

Références

Front Immunol. 2021 May 05;12:626616
pubmed: 34025638
Exp Hematol Oncol. 2021 Dec 18;10(1):56
pubmed: 34922633
Front Bioeng Biotechnol. 2022 Feb 21;10:810180
pubmed: 35265596
Biotechnol Lett. 2015 Nov;37(11):2121-37
pubmed: 26153348
J Immunol. 2003 May 1;170(9):4854-61
pubmed: 12728922
MAbs. 2022 Jan-Dec;14(1):2044435
pubmed: 35239451
Transplantation. 1999 Aug 27;68(4):563-71
pubmed: 10480417
Sci Rep. 2017 Aug 21;7(1):8360
pubmed: 28827777
Protein Eng. 1996 Jul;9(7):617-21
pubmed: 8844834
Methods. 2019 Feb 1;154:87-92
pubmed: 30081078
Sci Rep. 2021 Sep 30;11(1):19411
pubmed: 34593913
Methods. 2019 Feb 1;154:32-37
pubmed: 30308314
Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11187-92
pubmed: 21690412
JCI Insight. 2020 Apr 9;5(7):
pubmed: 32271166
J Exp Clin Cancer Res. 2019 Aug 14;38(1):355
pubmed: 31412896
J Biol Chem. 2007 Sep 21;282(38):27659-65
pubmed: 17644522
Protein Eng Des Sel. 2017 Jan;30(1):15-21
pubmed: 27881685
Biochemistry. 1998 May 12;37(19):6833-7
pubmed: 9578569
Nat Med. 2012 Oct;18(10):1570-4
pubmed: 23023498
Proc Natl Acad Sci U S A. 1992 May 15;89(10):4285-9
pubmed: 1350088
J Am Chem Soc. 2016 Feb 24;138(7):2162-5
pubmed: 26854538
MAbs. 2017 Oct;9(7):1118-1128
pubmed: 28692328
Biochem Biophys Res Commun. 2020 Feb 26;523(1):72-77
pubmed: 31831177
Drug Discov Today. 2015 Jul;20(7):838-47
pubmed: 25728220
Mol Med Rep. 2015 Jul;12(1):147-54
pubmed: 25760691
Chem Sci. 2014;5(1):446-461
pubmed: 24634716
Cancer Immunol Immunother. 2007 Mar;56(3):303-317
pubmed: 16738850
MAbs. 2017 Feb/Mar;9(2):182-212
pubmed: 28071970
Biomedicines. 2021 Jun 03;9(6):
pubmed: 34204931

Auteurs

Risa Yamada (R)

Graduate School of Science and Engineering, Yamagata University, 4-3-16 Jyonan, Yonezawa, Yamagata, 992-8510, Japan.

Ishin Nakahara (I)

Department of Biotechnology and Life Science, Graduate School of Engineering, Tokyo University of Agriculture and Technology, 2-24-16 Naka-cho, Koganei, Tokyo, 183-8538, Japan.

Izumi Kumagai (I)

Department of Biotechnology and Life Science, Graduate School of Engineering, Tokyo University of Agriculture and Technology, 2-24-16 Naka-cho, Koganei, Tokyo, 183-8538, Japan.

Ryutaro Asano (R)

Department of Biotechnology and Life Science, Graduate School of Engineering, Tokyo University of Agriculture and Technology, 2-24-16 Naka-cho, Koganei, Tokyo, 183-8538, Japan.

Takeshi Nakanishi (T)

Division of Science and Engineering for Materials, Chemistry and Biology, Department of Chemistry and Bioengineering, Graduate School of Engineering, Osaka Metropolitan University, Sugimoto 3-3-138, Sumiyoshi-ku, Osaka, 558-8585, Japan.

Koki Makabe (K)

Graduate School of Science and Engineering, Yamagata University, 4-3-16 Jyonan, Yonezawa, Yamagata, 992-8510, Japan. makabe@yz.yamagata-u.ac.jp.

Articles similaires

Absolute concentration estimation of COVID-19 convalescent and post-vaccination IgG antibodies.

Melvin E Klegerman, Tao Peng, Ira Seferovich et al.
1.00
Humans COVID-19 Immunoglobulin G Antibodies, Viral SARS-CoV-2

Generation of binder-format-payload conjugate-matrices by antibody chain-exchange.

Vedran Vasic, Steffen Dickopf, Nadine Spranger et al.
1.00
Immunoconjugates Humans Antibodies, Bispecific Receptor, ErbB-2 Cell Line, Tumor

Polarization toward Tfh2 cell involved in development of MBC and antibody responses against Plasmodium vivax infection.

Pongsakorn Thawornpan, Zulfa Zahra Salsabila, Piyawan Kochayoo et al.
1.00
Humans Malaria, Vivax Plasmodium vivax Antibodies, Protozoan Adult

Assessment of disability and disease burden in neuromyelitis optica spectrum disorders in the CIRCLES Cohort.

Shervin Gholizadeh, Alex Exuzides, Jennifer Sinnott et al.
1.00
Humans Neuromyelitis Optica Female Male Middle Aged

Classifications MeSH

questionsmedicales.fr › Phénomènes chimiques › Phénomènes biochimiques › Intéines › Construction of IgG-Fab
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Maturation post-transcriptionnelle des ARN › Épissage des ARN › Épissage en trans › Construction of IgG-Fab
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps bispécifiques › Construction of IgG-Fab
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Modification traductionnelle des protéines › Maturation post-traductionnelle des protéines › Épissage des protéines › Construction of IgG-Fab
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Isotypes des immunoglobulines › Immunoglobuline G › Construction of IgG-Fab